

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Taik Koo Yun et al. Conf.: 6452

Appl. No.: 10/614,176 Group: 1654

Filed: July 8, 2003 Examiner: COE, S.D.

For: CANCER PREVENTIVE COMPOSITION COMPRISING
GINSENOSIDE Rg₅ OR Rh₂ COMPONENTS OF
GINSENG (**AS AMENDED**)

SMALL ENTITY TRANSMITTAL FORM

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

January 12, 2005

Sir:

Transmitted herewith is a reply in the above-identified application.

- ☐ Applicant claims small entity status under 37 C.F.R. § 1.27.
- ☐ The enclosed document is being transmitted via the Certificate of Mailing provisions of 37 C.F.R. § 1.8.
- ☐ The enclosed document is being transmitted via facsimile.

The fee has been calculated as shown below:


	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	12	-	20	=	0	\$25	\$0.00
INDEPENDENT	2	-	3	=	0	\$100	\$0.00
<input type="checkbox"/> FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM						\$180	\$0.00
						TOTAL	\$0.00

- ☒ Petition for two (2) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$225.00 for the extension of time.
- ☐ No fee is required.
- ☒ Check(s) in the amount of \$225.00 is(are) enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. §§1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By  #42,874
for Joseph A. Kolasch, #22,463

JAK/CAM:cms
0662-0189P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment(s)



PATENT
0662-0189P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Taik Koo YUN et al. Conf.: 6452
Appl. No.: 10/614,176 Group: 1654
Filed: July 8, 2003 Examiner: COE, S.D.
For: CANCER PREVENTIVE COMPOSITION
COMPRISING GINSENOSIDE Rg₅ OR Rh₂
COMPONENTS OF GINSENG (**AS AMENDED**)

REPLY UNDER 37 C.F.R. § 1.111

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

January 12, 2005

Sir:

In reply to the Office Action dated August 12, 2004, the period for reply having been extended two months to January 12, 2005, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

This reply includes: Amendments to the Specification;

01/14/2005 MAHMED1 00000057 10614176

01 FC:2252

225.00 OP